Katy JEANNOT

Katy JEANNOT is a Clinical Professor affiliated with the University of Bourgogne Franche-Comté and the CHU Besançon Hospital. Her research focuses on antibiotic resistance mechanisms in Pseudomonas aeruginosa and Acinetobacter baumannii, including efflux pumps, genetic determinants of resistance, and adaptations to antimicrobial peptides. She investigates clinical isolates from cystic fibrosis patients, analyzing their phenotypic and genotypic evolution.

Her work spans epidemiological studies of antibiotic resistance, such as the 2023–24 Mycoplasma pneumoniae outbreak in France, and evaluates new antimicrobial agents like cefiderocol and murepavadin. She collaborates on projects involving rapid diagnostic tests for carbapenemases and genomic studies of high-risk bacterial clones.

Key research areas include multidrug resistance mechanisms, envelope stress responses, and the development of novel antimicrobial strategies. She has contributed to clinical trials assessing compassionate use of antibiotics and has authored/co-authored over 80 peer-reviewed articles, emphasizing global antibiotic resistance surveillance and molecular epidemiology.

• Affiliations: CHU Besançon, UMR 6249 Chrono-Environnement, University of Bourgogne Franche-Comté
• Labs/Teams: Involved in multidisciplinary teams studying microbial pathogenesis and antimicrobial resistance.